Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Simple Summary Although rare, hemophagocytic lymphohistiocytosis (HLH), a syndrome of severe, dysregulated inflammation, is associated with poor survival when it occurs in conjunction with malignancy. This review discusses how published methods for diagnosing HLH can be applied in the setting of adult patients presenting with malignancy-associated HLH (mHLH) and offers evidence-based recommendations for the management of this clinically challenging scenario. Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of severe, dysregulated inflammation driven by the inability of T cells to clear an antigenic target. When associated with malignancy (mHLH), the HLH syndrome is typically associated with extremely poor survival. Here, we review the diagnosis of secondary HLH (sHLH) syndromes in adults, with emphasis on the appropriate workup and treatment of mHLH. At present, the management of HLH in adults, including most forms of mHLH, is based on the use of corticosteroids and etoposide following the HLH-94 regimen. In some cases, this therapeutic approach may be cohesively incorporated into malignancy-directed therapy, while in other cases, the decision about whether to treat HLH prior to initiating other therapies may be more complicated. Recent studies exploring the efficacy of other agents in HLH, in particular ruxolitinib, offer hope for better outcomes in the management of mHLH. Considerations for the management of lymphoma-associated mHLH, as well as other forms of mHLH and immunotherapy treatment-related HLH, are discussed.